Queensland Gold Hills Announces Acquisition of Mia Lithium Project in Quebec Hosting 8km Spodumene-Pegmatite Trend and Concurrent Private Placement Financing

Vancouver, BC, Nov 28, 2022 – (ACN Newswire) – Queensland Gold Hills Corp. (TSXV: OZAU) (OTCQB: MNNFF) ("Queensland Gold" or the "Company") is pleased to announce that it has entered into an agreement with an effective date of November 21, 2022 (the "Purchase Agreement") with 9219-8845 QC Inc., a private Quebec company dba Canadian Mining House ("CMH") and certain investors in CMH ("CMH Nominees") to acquire a 100% interest in the 86 square kilometre Mia Lithium Property (the "Property") in the James Bay area of Quebec, Canada (the "Acquisition").


Figure 1 – Mia Lithium Property Regional Location

Figure 2 – Mia Lithium Property


President & CEO Alicia Milne states, "Our entry into the lithium space represents a new value creation opportunity for our shareholders. Quebec is a top global mining jurisdiction and the James Bay region is a highly attractive investment destination for lithium exploration due to its prolific hard rock lithium endowment. We are looking forward to revealing the enormous potential we see in the Mia project."

About the Mia Lithium Property

The Mia Property is comprised of 170 mineral claims, located 62 km East of Wemindji Community in the Eeyou Itschee Territory, James Bay, Quebec. The lithium mineral showings are located approximately 10 kilometres from the nearest highway.

The Property geology is part of the Yasinski Lake area, identified by narrow greenstone belt slivers, belonging to volcanic rocks and related sediment the Yasinski Group and pierced by syn-tectonic tonalite and granodiorite suite. The Property is situated in the western extremity of this geological area, covering various lithologies and favourable structures, known to host spodumene bearing pegmatites. The southern half of the Property covers a northeast limb of the Vieux Comptoir granite and a concordant intrusive body described as a spodumene granite on SIGEOM, the Quebec provincial government's geomining information system: https://sigeom.mines.gouv.qc.ca/signet/classes/I1108_afchCarteIntr.

Historical work by Main Exploration Company Ltd. in 1959 (GM10200) reported several spodumene-bearing pegmatites on the Property and mapped an 8.3 km trend of discontinuous pegmatite intrusions. SIGEOM lists nine metallic deposits directly on the Mia Lithium property including two for lithium, namely Mia Li-1 and Mia Li-2. Carte 1879 is listed as a spodumene mineral deposit as no assays were recorded for it.

The westernmost mineral showings Mia-Li1 and Mia-Li2 were sampled in 1997 by Quebec government geologists and assays returned grades of 0.47% Li2O and 2.27% Li2O respectively. Numerous pegmatite intrusions have been recorded along the 8.3 km long trend but were never followed up for their lithium potential. The 1959 report also details that the pegmatite dykes are as much as 100 feet (30.5 metres) in width and are commonly zoned, with spodumene crystals described as being as much as 2 feet (0.61 metres) in length.

Acquisition Terms:

Subject to TSX Venture Exchange (the "TSXV") acceptance, pursuant to the terms of the Purchase Agreement, the Company will acquire the Property from CMH for total consideration of an aggregate of 13,000,000 common shares of the Company (the "Consideration Shares"), $500,000 (the "Cash Consideration") and $1,000,000 in exploration expenditures as follows:

– 6,500,000 Consideration Shares and $200,000 within 3 days of TSXV acceptance of the Acquisition (the "Effective Date");
– 6,500,000 Consideration Shares and $150,000 on the six-month anniversary of Effective Date; and
– Incur $1,000,000 in exploration expenditures on the Property and $150,000 on the one-year anniversary of the Effective Date (the "Closing Date").

The Company will earn a 100% interest in the Property on the Closing Date.

CMH has directed that a portion of the Acquisition Shares and Cash Consideration be issued and paid to the CMH Nominees.

CMH will retain up to a maximum of a 3% net smelter returns royalty, of which up to 1% can be repurchased by the Company at any time prior to commercial production for $1,000,000. No finder's fee is payable in connection with the Acquisition. The Property is subject to an existing 2% net smelter returns royalty granted by CMH (as assignee) in favour of Franco-Nevada Corporation on certain minerals claims forming a part of the Property as well as an existing 2% net smelter returns royalty granted by CMH in favour of Eastmain Resources Inc. on certain mineral claims forming part of the Property. On the Closing Date, the Company will assume the obligations under these existing royalties.

The Acquisition remains subject to TSXV acceptance.

Private Placement

Queensland will be conducting a non-brokered private placement of up to 12,500,000 units (each, a "Unit") at a price of $0.10 per Unit for gross proceeds of up to $1,250,000 (the "Offering"). Each Unit will consist of one common share of the Company (each, a "Share") and one half of one common share purchase warrant (each whole warrant, a "Warrant"). Each Warrant exercisable into one additional Share at a price of $0.25 for two years after the date of issuance. Closing of the Offering is subject to the acceptance of the TSXV. The Company intends to use the proceeds of the Offering to commence a comprehensive review of all historical data related to the Mia Lithium Property in preparation for a field exploration campaign and for general working capital.

All securities to be issued under the Offering will be subject to a statutory hold period expiring four months and one day from the date of issuance. The Company anticipates that the majority of the subscriptions will be from arm's length parties, although insiders may participate in the Offering. The Company may pay finders' fees on the Offering, as permitted by applicable securities.

QP Disclosure

Neil McCallum, B.Sc., P.Geo., of Dahrouge Geological Consulting Ltd., a registered permit holder with the Ordre des Geologues du Quebec and Qualified Person as defined by National Instrument 43-101 – Standards of Disclosure for Mineral Projects, supervised the preparation of the technical information in this news release.

About Queensland

Queensland Gold Hills is mineral exploration company currently advancing exploration of two gold projects located in the historic goldfields of Queensland, Australia: the Big Hill Gold Project and the Titan Project which collectively cover 110 square kilometers in the Talgai Goldfields of the broader Warwick-Texas District and host 54 high-grade historical gold mines.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Alicia Milne
President & CEO
amilne@queenslandgoldhills.com

Kevin Bottomley
Director
kbottomley@queenslandgoldhills.com

Telephone: 1 (800) 482-7560
E-mail: info@queenslandgoldhills.com
Twitter: @QLDGoldhills

Forward-Looking Statements

This news release may contain forward-looking statements and forward-looking information (collectively, "forward-looking statements") within the meaning of applicable Canadian legislation. Forward-looking statements are typically identified by words such as: "believes", "expects", "anticipates", "intends", "estimates", "plans", "may", "should", "would", "will", "potential", "scheduled" or variations of such words and phrases and similar expressions, which, by their nature, refer to future events or results that may, could, would, might or will occur or be taken or achieved. Accordingly, all statements in this news release that are not purely historical are forward-looking statements and include statements regarding beliefs, plans, expectations and orientations regarding the future including, without limitation, any statements or plans regard the geological prospects of the Company's properties and the future exploration endeavors of the Company. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Forward-looking statements are based on a number of material factors and assumptions. Factors that could cause actual results to differ materially from those in forward-looking statements include failure to obtain necessary approvals, unsuccessful exploration results, changes in project parameters as plans continue to be refined, results of future resource estimates, future metal prices, availability of capital and financing on acceptable terms, general economic, market or business conditions, risks associated with regulatory changes, defects in title, availability of personnel, materials and equipment on a timely basis, accidents or equipment breakdowns, uninsured risks, delays in receiving government approvals, unanticipated environmental impacts on operations and costs to remedy same. Readers are cautioned that mineral exploration and development of mines is an inherently risky business and accordingly, the actual events may differ materially from those projected in the forward-looking statements. Additional risk factors are discussed in the section entitled "Risk Factors" in the Company's Management Discussion and Analysis for its recently completed fiscal period, which is available under Company's SEDAR profile at www.sedar.com.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Copyright 2022 ACN Newswire. All rights reserved. http://www.acnnewswire.com

GMEX Group Wins Best Development in FinTech of the Year

LONDON, Nov 28, 2022 – (ACN Newswire) – GMEX Group ('GMEX'), a leader in digital business and technology solutions for capital markets, is proud to announce that it has been awarded Best Development in FinTech of the Year by Crypto AM for its GMEX Pyctor institutional-grade digital assets technology. These coveted awards are judged by an independent, expert panel of industry leaders. GMEX competed with other finalists including Revolut to win.

GMEX Pyctor ('Pyctor') was acquired earlier this year by GMEX after being successfully incubated in ING Neo's innovation lab. It has been jointly developed in collaboration with multiple blue-chip financial institutions (both asset managers and banks) and regulators. This leading fintech provides regulatory compliant digital assets network and digital custody technology, and is designed for firms operating in regulated environments. It offers highly secure digital custody and transactional network services for a broad range of digital assets, as well as delivering interoperability between permissioned and public blockchains.

GMEX Group is in its tenth anniversary year. While its business started in traditional finance, developing exchange matching engines, clearing, settlement and custodial solutions, the firm was early to get involved in the digital assets space in 2017 with the subsequent launch of the GMEX Fusion, a unique centralised and distributed ledger market infrastructure suite for exchanges and post trade operators. It now has multiple solutions as part of an overall technology fabric, including its MultiHub 'network of networks' service, which interfaces with Pyctor, removing the need to integrate with multiple trading parties, trading venues and digital custodians. Sitting at that intersection, GMEX is a hybrid finance specialist, addressing the interoperability issues experienced in the market to bridge traditional and digital assets activity aligned with current and evolving regulations.

Hirander Misra, CEO of GMEX Group said: "The current environment will lead to increased regulations and an institutional digital flight to quality, creating a need for an offering which makes it easier navigate this with the right governance, control, security and risk management."

He continued, "GMEX Group is the first company to offer an end-to-end multi-asset, multi-sector Hybrid Finance solution designed for regulated environments, which bridges the gap between off-chain Traditional Finance (TradFi), Centralized Finance (CeFi) and on-chain Decentralized Finance (DeFi) across jurisdictions. We are pioneering in the domain of Hybrid Finance (HyFi) and are thrilled to have our success in developing unique solutions to address industry challenges formally recognised with this highly prestigious award."

Media Contact:
GMEX Group
Helen Disney
The Realization Group
Tel: +44 (0)7792 376 546
Helen.disney@therealizationgroup.com
pr@gmex-group.com

Copyright 2022 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Kitchen Culture Says 5 Directors Will Remain on its Board as Purported EGM Held Last Friday Is Invalid; Asks Requisitioners to Put Matters Before Singapore Court

SINGAPORE, Nov 28, 2022 – (ACN Newswire) – Kitchen Culture Holdings Ltd. ("Kitchen Culture" or the "Company") said today that 5 directors that requisitioners sought to replace through a purported Extraordinary General Meeting last Friday ("Purported EGM") will remain. Instead, the Company deems the meeting and resolutions purportedly passed to be invalid, and has asked the requisitioners to put the matter before the Singapore Court.

Responding to a press release issued on 25 November 2022 on ACN Newswire by the 8 requisitioners, Kitchen Culture said it had written the same day to lawyers for the latter asking for key information. As at 12 noon today, the requisitioners' lawyers had yet to send documentation such as executed proxy forms, list of attendees, who chaired the meeting purportedly held electronically at 9.00 am last Friday, and the breakdown of votes and questions raised or answered at the meeting.

This has prevented the directors from having "… the opportunity to make a proper assessment of the conduct and processes at the so-called meeting, and take professional advice as necessary,' the Company said. Instead, the requisitioners were "… creating and maintaining uncertainty and confusion by claiming success of the 'New Board" through press releases and the media.

The requisitioners appeared to have rushed to issue their 25 November press release "without bothering to inform the Company of such status." Notwithstanding this, the Company has been trying to engage them to ensure that there is clarity of the situation and to avoid further uncertainty and confusion sown by such conduct, Kitchen Culture said.

The Company had announced that the Purported EGM – the second attempt by the requisitioners to remove 5 of 6 existing directors – was invalid as it is in non-compliance with the Companies Act 1967 and breached the Company's Constitution. Instead of giving proper notice, the requisitioners issued a single newspaper advertisement.

Over the past weekend, the Company has received numerous letters of protest and complaints from various shareholders, objecting to the so-called holding of the Purported EGM in spite of its invalidity. "Some shareholders also complained that they did not receive any notice… and were therefore not in a position to consider attending it," the Company said.

The Company, through its lawyers, has written again to lawyers of the requisitioners to invite them to apply to the Court to determine whatever issues from which they differ, with respect to the Company's position.

The Directors (save for, and unlike, Mdm Hao) consider that this is "the most appropriate way to resolve any differences or contentions (and to put to rest the uncertainty and confusion)" as to the validity of the Purported EGM and the resolutions they claim to have been passed, and the eligibility of the persons they claim to have been elected to the office of Director of the Company.

Kitchen Culture said each of the 5 persons named by requisitioners to be members of the new 6-member board were ineligible to be put up for election in the first place as they had failed, neglected or refused to submit important relevant documents on time, even assuming that it was a valid general meeting of the Company.

The 5 persons proposed by the requisitioners are James Beeland Rogers, Jr., Yip Kean Mun, Lam Kwong Fai, Tan Meng Shern and Cheung Wai Mun. The Requisitioners comprise OOWAY Group Ltd. ("OOWAY") – the Company's largest shareholder – and 7 individuals who own an aggregate of 21.71% of the Company's shares.

Kitchen Culture's Board, with the exception of Madam Hao Dongting ("Mdm Hao"), has said that there are no grounds to justify the resignations of the 5 current directors – Mr Lim Wee Li (Executive Director), Mr Lau Kay Heng (Non-Executive Non-Independent Chairman), and 3 Independent Directors, Mr Ang Lian Kiat, Mr William Teo Choon Kow and Mr Peter Lim King Soon.

Mr Lau Kay Heng and Mr Peter Lim King Soon were named as new directors on 15 July 2022, the same day that Mr Lincoln Teo, an OOWAY representative and former Interim CEO of Kitchen Culture, ceased to be Executive Director. The Company stressed that OOWAY had in fact supported the re-appointments of Mr William Teo Choon Kow and Mr Ang Lian Kiat at the Annual General Meeting held on 18 March 2022.

"The Directors of the Company (other than Mdm Hao) urge all shareholders to be wary of and not to be unduly influenced by media statements emanating from or ascribed to OOWAY Group or any of the other 7 Relevant Shareholders or any of the 5 persons who were claimed to have been elected to the "New Board". Shareholders are advised to refer to and compare against announcements and press releases of the Company," Kitchen Culture said.

Kitchen Culture shares have been suspended from trading since July 2021. Its Board has seen several changes since the involvement of OOWAY in October 2020.

Issued by:
Kitchen Culture Holdings Ltd.
9 Raffles Place, #52-02, Republic Plaza
Singapore 048619
Tel: +65 6471 6776, Fax: +65 6472 6776

Media & Investor Contact
Whatsapp (Text): +65 9748 0688
kitchenculture@wer1.net

This press release has been reviewed by the Company's sponsor, SAC Capital Private Limited (the "Sponsor"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "SGX-ST") and the SGX-ST assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Ms. Lee Khai Yinn (Tel +65 6232 3210), at 1 Robinson Road, #21-00 AIA Tower, Singapore 048542.

Kitchen Culture Holdings Ltd. [SGX: 5TI] [BBG: KCH:SP] [RIC: KCHL.SI] https://kcholdings.com.sg

Copyright 2022 ACN Newswire. All rights reserved. http://www.acnnewswire.com

The Executive Talk by ShareInvestor: Boutique Corp PCL (SET: BC)

BANGKOK, Nov 28, 2022 – (ACN Newswire) – Boutique Corporation PCL (SET: BC) President and Group CEO, Mr. Prabsharan Singh Thakral provided an admirable interview regarding his business strategy after Covid-19, diversification and embracing digital technology is the strategic approach for Boutique Corporation to remain resilient.

1. Against a challenging business environment significantly impacted by the Covid-19 pandemic, what's your view toward the Thai hospitality and commercial industry this year and in 2023?

The COVID-19 pandemic has been one of the major challenges for Thailand's beauty industry and our company. We must refine our strategies and business plans to cope with the ever-changing market and rapidly changing consumer behavior.

Regarding the long-term strategy, we aim to increase our top line to 3,000 million baht by 2026. Our focus remains on beauty and health products, such as skincare, makeup, hair color, and food supplements, which align with the company's vision and mission: To be Asia's leading beauty and health company by creating the best innovation to fulfil everyone's demand and inspiring people across Thailand and Asia.

2. Against a challenging business environment significantly impacted by the Covid-19 pandemic, what's your view toward the Thai hospitality and commercial industry this year and in 2023?

This year, we begin to see a recovery in tourism, with approximately 10 million tourists coming into the country. We see India as a large component of tourists coming to the country, with about 1 million travellers forecast for the end of this year. We see, toward the end of next year, perhaps the normalization of tourism in this country. But, of course, we also have to wait until China opens up for tourism.

Meanwhile, we should look for other opportunities instead of focusing on China. These whole few years have taught us that we should begin to penetrate new markets. Currently, we have an excellent new market like Saudi coming in. We should focus on and harness the demand from other large markets like India so that our economy relies on something different than a single market like China. Our marketing activities for tourist companies or Thailand Tourism Authority (TAT) should bear that in mind as we come out of Covid.

3. As the property development company, how has Covid impacted your business, and how is it currently going?

Yes, our main business is building property for existence. That continues during Covid. We were very successful last year in existing an asset in Sukhumvit Soi 23 at the pre-covid valuation. We have just completed Oakwood Sukhumvit Soi 36, a hotel by the Thong lor BTS station, opening on the first of October. Even before its first month of full operation, we had a buyer coming and signing a sale agreement with us, buying it at the valuation as well. This business continues.

However, the industry and, of course, Boutique Corporation were affected by the disrupted cash flow coming through the hotel. So, Covid has been a learning for many business leaders. One of the things I saw to undertake during Covid was to embrace diversification, ensuring that after Covid, we would have multiple business lines that have synergistic approaches with our current business.

4. Boutique corporation has expanded the ecosystem into logistics and healthcare. How have they turned out so far?

The first business we decided to expand into was cannabis and wellness associated with cannabis. From growing our high medical-grade cannabis to the dispensary, we are ultimately the country's first fully licensed value-chain cannabis key provider. We currently have two dispensaries, the first one at Sukhumvit Soi 16, in one of our properties. So, this is the synergistic approach. And here, at the Summer Point Mall, our second dispensary, which represents our wellness concept. We can issue a prescription for oil and cannabis medicine based on traditional Thai formulas. As a result, the cannabis-related healthcare business is one of the diversifications we undertook to ensure that we, as a company, are sustainable and more resilient.

5. What are your key strategies for the next year?

For cannabis, we see solid sales in our dispensaries, high demand for premium-grade and high-quality medical-grade cannabis dry flowers, and an increase in repeat customers who enjoy the quality and comfort of our pure and toxin-free cannabis. In addition, we are confident in our products and service because they were all tasted by the ministry of health. Ultimately, we aim to accelerate our rollout and expand the business to 20 outlets within the following year.

The second diversification we recently undertook is a self-storage and the logistics of door-to-door delivery from storage. Again, the business is new and has just opened this month. And we already begin to see good demand for self-storage. So, we aim to drive growth in this unit as well.

And, of course, we do foresee that hospitality will come back, so we continue to develop assets for the existing. Next year we are looking at developing Sukhumvit Soi 5, one of our pipeline's assets. We are preparing to establish another retail development on Charoenkrung road, in front of the Shrewsbury International School. And other projects that we have in our pipeline.

6. Amid the growing digital economy, how has it affected your company?

There are two aspects of the digital economy and how it affects the company. One is how we apply digital technology at work, and two is embracing it within our businesses. For the former, the way we work, such as working from home and using online platforms for a meeting. We all have already familiar with the technology and work in a hybrid way. We ensure that our company is tech-savaged enough to embrace that.

However, what is more important is how we embrace new technology to create a synergistic effect with our business. Hence, in February this year, we launched our first NFTs linking to cannabis. They were limited and connected to every single seed plant we grew on our cannabis farm. Buyers of these NFTs effectively received a utility over our cannabis platform, either to get discounts or special access. This exemplifies how we synergize emerging technology like blockchain with our businesses. So, we also corporate those synergistic approaches with our other business units, such as hospitality, real estate, and self-storage, that we are expanding right now.

7. How do you envision your business in 5 years? How have you embraced the sustainability concept?

Despite the Covid situation, building and selling assets continues to have good demand, especially in a good location. In October, we opened our first third-party-managed hotel under our brand "Jono", which is in Karon beach, Phuket. So, we will drive and grow this business exponentially. For the sustainability part, over the next five years, we will continue to ramp up the growth of our cannabis outlet across the Thai market, mainly tourists, ex-pats, and the high entire. We will also grow our self-storage, logistics, and hospitality business. So, there are many opportunities that we can diversify our ecosystem, create synergistic approaches, and remain resilient.

Watch Executive Talk by ShareInvestor on YouTube ShareInvestor Thailand
https://www.youtube.com/watch?v=IdeXSZwRPM8&ab_channel=ShareInvestorThailand

About The Executive Q&A Series

The Executive Q&A Series is presented by ShareInvestor, Asia's leading financial internet media and technology company and the largest investor relations network in the region. For more information, email admin.th@shareinvestor.com, and visit our Website: www.ShareInvestorThailand.com.

Copyright 2022 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Dubai UAE’s MxHub Announces launch of MX100 Investor Event

DUBAI, UAE, Nov 28, 2022 – (ACN Newswire) – MxHub, Dubai's newest Innovation Center and Incubator has announced the launch of MX100, a multimedia metaverse event scheduled for December 20, 2022 next to the Burj Khalifa in Dubai UAE. The event is geared to deliver the latest in innovative startups from throughout the region amidst a backdrop of the latest metaverse centric technologies.



"In our effort to bring the latest technological breakthroughs of the Metaverse to the UAE, we are planning this showcase event via a multimedia delivery that we believe is transforming the way events are produced, delivered and engaged with," stated Edward Musinski, Executive Director of MxHub. "Our growing ecosystem drives both investor awareness and a showcasing medium for best of class opportunities through the sector that encompasses fintech, blockchain, healthtech & web3."

Invited Investors include: Andreeson Horowitz, Sequoia, TigerGlobal and SALD Investments

The event which is being produced by MxHub is supported by the following MxHub companies.

Blockbytes: https://bloxbytes.com/
MetaVibes: https://metavibes.ai/
Citizen of Metaland: https://www.citizenofmetaland.com/
Ducatus: http://www.ducatus.com/
VisionTech: https://www.visiontechme.com/
Bimar: https://www.bimar.pro/main-en
Arcona: https://www.arcona.space/
Vatom: https://www.vatom.com/
Aimedis: http://www.aimedis.io/
Panvora: http://www.panvora.com/
MetaAlliance: https://www.metaalliance.biz/
Huma: https://huma.com
Mobio: https://mobiointeractive.com
Shaikhtech: https://www.shaikhtech.com/
MatterFi: https://matterfi.com

Event Video: www.youtube.com/watch?v=DbdQkQeT9xg
Event URL: https://mx100.vip/

About MxHub

MxHub is a UAE based Innovation Ecosystem and is part of Phygital Holdings a UAE Digital Holdings Fund. The company hosts multiple global companies by providing corporate infrastructure support to its growing ecosystem of innovative startups. MxHub is a one stop startup incubator for startups located outside of Dubai and provides a full range of support services to companies looking to embed themselves in the local UAE market. For more information, visit https://mxhub.co.

Copyright 2022 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Society Pass Inc Integrates with Stripe Inc’s Payments Platform

SINGAPORE, Nov 28, 2022 – (ACN Newswire) – Society Pass Incorporated ("SoPa") (Nasdaq: SOPA), Southeast Asia's leading data-driven loyalty, fintech and e-commerce ecosystem, today announces the integration of Stripe's financial infrastructure solutions onto the SoPa platform to power transaction settlement services for merchants and customers on SoPa's ecosystem.

Leveraging Stripe's cutting-edge technology solutions, Society Pass expands the product and geographical reach of its ecosystem, simplifies payment flows, and accepts payments at scale in multiple currencies. In addition, SoPa leverages Stripe's anti-fraud technology, Stripe Radar, to detect and block fraud using machine learning. Merchants on SoPa's ecosystem utilise Stripe's payment infrastructure to accept credit and debit cards payments from customers, enable their customers to checkout in a simple way, and at the same time provide a superior shopping experience to consumers.

Rokas Sidlauskas, Chief Marketing Officer of Society Pass, comments, "We are thrilled to announce this integration with Stripe which provides diverse payment options to our consumers whilst streamlining the process for merchants to manage their finances and get paid faster. Since our incorporation, Society Pass has redefined the e-commerce experience for millions of registered consumers and hundreds of thousands of registered merchants in SEA. By offering convenience, flexibility, and control on both sides of the retail transaction, SoPa paves a win-win path for our merchants and consumers alike. Partnering with Stripe is an organic path to accelerate this goal".

As a global financial infrastructure platform, Stripe makes it easy for companies to launch, run and scale their business from day one. Stripe offers a broad set of software tools, including services like built-in-machine-learning powered fraud protection, advanced analytics and infrastructure that makes it easy for businesses of all sizes to scale locally and internationally, while reducing the time and resources spent on payments so they can focus on their core business.

Society Pass' first-in-class ecosystem transforms the entire retail value chain towards a more digital future in SEA. Looking ahead, SoPa will continue to simplify the use and access to online shopping, leveraging cutting edge technologies and capabilities to tailor more intelligent, individualized, and contextual experiences for the next generation consumers. In addition, SoPa is committed to make continuous efforts in reinforcing and diversifying its ecosystem by means of strategic acquisitions of market-leading companies and partnerships with visionary entrepreneurs in six distinct B2C e-commerce verticals: loyalty, lifestyle, food & beverage delivery, telecoms, digital marketing, and travel.

About Society Pass Inc.

Founded in 2018 as a data-driven loyalty, fintech and e-commerce ecosystem in the fast-growing markets of Vietnam, Indonesia, Philippines, Singapore and Thailand, which account for more than 80% of the SEA population, and with offices located in Angeles, Bangkok, Hanoi, Ho Chi Minh City, Jakarta, Manila, and Singapore, Society Pass Incorporated (Nasdaq: SOPA) is an acquisition-focused holding company operating 6 interconnected verticals (loyalty, digital media, travel, telecoms, lifestyle, and F&B), which seamlessly connects millions of registered consumers and hundreds of thousands of registered merchants/brands across multiple product and service categories throughout SEA.

Society Pass completed an initial public offering and began trading on the Nasdaq under the ticker SOPA in November 2021. SOPA shares were added to the Russell 2000 index in December 2021.

SoPa acquires fast growing e-commerce companies and expands its user base across a robust product and service ecosystem. SoPa integrates these complementary businesses through its signature Society Pass fintech platform and circulation of its universal loyalty points or Society Points, which has entered beta testing and is expected to launch broadly at the beginning of 2023. Society Pass loyalty program members earn and redeem Society Points and receive personalised promotions based on SoPa's data capabilities and understanding of consumer shopping behaviour. SoPa has amassed more than 3.3 million registered consumers and over 205,000 registered merchants and brands. It has invested 2+ years building proprietary IT architecture to effectively scale and support its consumers, merchants, and acquisitions.

Society Pass leverages technology to tailor a more personalised experience for customers in the purchase journey and to transform the entire retail value chain in SEA. SoPa operates Thoughtful Media Group, a Thailand-based, a social commerce-focused, premium digital video multi-platform network; NusaTrip, a leading Indonesia-based Online Travel Agency; Gorilla Networks, a Singapore-based, web3-enabled mobile blockchain network operator; Leflair.com, Vietnam's leading lifestyle e-commerce platform; Pushkart.ph, a popular grocery delivery company in Philippines; Handycart.vn, a leading online restaurant delivery service based in Vietnam; and Mangan.ph, a leading local restaurant delivery service in Philippines.

For more information on Society Pass, please check out:
Website at https://www.thesocietypass.com or
LinkedIn at https://www.linkedin.com/company/societypass or
Facebook at https://www.facebook.com/thesocietypass or
Twitter at https://twitter.com/society_pass or
Instagram at https://www.instagram.com/societypass/.

Cautionary Note Concerning Forward-Looking Statements

This press release may include "forward-looking statements," within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact included in this press release are forward-looking statements. When used in this press release, words such as "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to us or our management team, identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, the Company's management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors detailed in the Company's filings with the SEC. All subsequent written or oral forward-looking statements attributable to us or persons acting on our behalf are qualified in their entirety by this paragraph. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's registration statement and prospectus relating to the Company's initial public offering filed with the SEC. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Media Contacts:
PRecious Communications
sopa@preciouscomms.com

Copyright 2022 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Tianda Pharma Announces 2022/23 Interim Results

HONG KONG, Nov 25, 2022 – (ACN Newswire) – Tianda Pharmaceuticals Limited ("Tianda Pharma" or "the Group"; stock code: 0455.HK) today announced its interim results for the six months ended 30 September 2022 ("the Period"). During the Period, the Group adopted proactive marketing strategy and improved its results notably. Its revenue increased by 5.6% to approximately HK$250 million. Gross profit rose by 10.2% to approximately HK$120 million and profit before taxation, depreciation and amortization turned around from loss of HK$6.9 million in the same period last year to profit of HK$2.3 million for the period.

Recorded strong sales of core products and continued to optimize Chinese medicine business layout
The Group has worked hard cultivating the cardiovascular, cerebrovascular and pediatric disease realms and owns unique generic product pipelines. Boasting notable efficacy and competitive price, Tuoping Valsartan capsules, the Group's core product for treating cardio-cerebrovascular disease, has been ranked the No. 1 best-selling product in its category in Mainland China since the success in securing first place in the nation's Centralized Drug Procurement. During the Period, sales of the product reached HK$92.3 million, representing a year-on-year growth of approximately 21%. Tuoen Ibuprofen oral suspension, a pediatric drug, was among the top three in terms of market share in the country due to effective marketing, achieving strong sales of HK$64.0 million for the Period, up approximately 70% year-on-year.

The Group has basically built for itself a complete traditional Chinese medicine ("TCM") industrial chain, from trading of Chinese medicinal materials, TCM decoction pieces and formula granules to innovative Chinese medicine R&D and international trade. During the Period, it continued to increase operating product varieties, expand sales channels and strengthen procurement sources, including exporting TCM decoction pieces to Australia and planning for importing to China special variety of Chinese medicinal materials from overseas. Insisted on the inheritance and innovation of TCM, it brought in innovative Chinese medicine transformation projects and embarked on cooperation in developing innovative Chinese medicines.

During the Period, overall revenue of TDMalls increased by 81%. The first clinic to adopt the equity investment cooperation model, TDMall (Tsim Sha Tsui) has famous medical experts as shareholders who also participate in the management. Starting to make profit eight months after opening, TDMall (Tsim Sha Tsui) provides valuable experience and serving as a model for expanding the business across the nation and worldwide. The Group is pushing forward with opening a TDMall in Shenzhen, another important step in expanding its presence in the Guangdong-Hong Kong-Macao Bay Area. The Group also continued to invest in "intelligent" development of Chinese medicines. The Chinese medicine cloud technology-based platform "TDMall on Cloud" of the Group played an important role in the Group's "Free Consultation and Medicine" charity campaign during the fifth wave of COVID-19 outbreaks in Hong Kong, offering comprehensive remote Chinese medicine services to the public.

Strengthened R&D across the board and capability to bring in business, actively expanded revenue sources
The Group has insisted on combining generic drug endeavors with innovation and, via its own R&D efforts and cooperation with external R&D institutions, continued to enrich its product pipelines. During the Period, the Group increased R&D investment, spending HK$12.0 million, up 260% year-on-year, set to allow it to come up with more new products that can become new and strong growth drivers for its medium and long-term development. The Group is currently pursuing 22 R&D projects, including class I innovative Chinese medicines, class III new Chinese medicines, class III chemical drug plus APIs, class IV chemical drugs and healthcare product series. During the Period, the Group actively introduced innovative Chinese medicine transformation projects in which the industry, academia, research and medical sectors come together to develop innovative Chinese medicines for treating chronic heart failure. Such initiatives have given the Group a rich and diversified product development portfolio that covers high-end generic drugs, classic Chinese medicines, modern Chinese medicines and healthcare products. The Group also actively introduced approved proprietary Chinese medicine products. Following the acquisition of the proprietary Chinese medicine product Xiaoer Qingre Zhike Granule last year, it acquired Jianerle Granule, a proprietary Chinese medicine for children during the Period, continuing to expand its pediatric product categories.

In addition, the Group launched contract development and manufacturing organization ("CDMO") and contract manufacturing organization ("CMO") businesses to expand its revenue sources and promote business development. As at the end of September 2022, it had seven contracts signed for R&D technology service mainly for liquid pharmaceutical preparations and completed production for two projects during the Period. The two business modes are expected to become growth drivers that can continuously generate revenue for the Group.

Stepped up efforts in three business segments, consolidated business foundation and achieved leapfrog development
To seize the opportunities in the continuously expanding pharmaceutical and healthcare market, the Group will keep growing its three business segments, namely Chinese medicines, medical and healthcare services and pharmaceuticals and medical technologies, in the future. It will also speed up bringing in products and product R&D, strengthen business expansion efforts, and investment and M&As, so as to achieve leapfrog development. For the Chinese medicine business, leveraging the country's policies to vigorously help the Chinese medicine industry develop, the Group will grasp the policy dividend of TCM and continue to develop the whole industry chain, increasing the trading of Chinese medicinal materials focusing on varieties, while accelerating the development of TCM decoction pieces and formula granules, which have huge market potential. It will also actively invest in the R&D and introduction of innovative Chinese medicines, classic ancient prescriptions of Chinese medicines, finished dosages and proprietary Chinese medicines. For its medical and healthcare services business, the Group will strengthen operation of the TDMalls and speeding up expansion via building its own clinics, franchising and mergers and acquisitions, and as well using different equity investment and cooperation modes. While prioritizing the development in the Guangdong-Hong Kong-Macao Bay Area, the Group will push for nationwide and global reach. At the same time, the Group will continue to improve and perfect its "TDMall on Cloud" app to "enhance user experience", for better online and offline integration, providing patients with convenient and intelligent high-quality Chinese medicine services. On the pharmaceuticals and medical technologies business front, the Group will strive to build up its core product brands such as Tuoping and Tuoen, focusing on developing cardio-cerebrovascular and pediatric products and consolidating relevant advantages. It will also expand its sales network to cover lower-tier markets so as to booster market share and actively expand CDMO and CMO business to boost revenue. In the future, it will apply 3D tactics (BD – business development, ID – investment and development, and R&D – research and development) in developing products with market potential, especially major product types, to provide impetus for long-term sustainable development.

About Tianda Pharmaceuticals Limited
Tianda Pharmaceuticals Limited ("Tianda Pharmaceuticals", listed on the Hong Kong Stock Exchange, stock code: 0455.HK) implements the following development strategies: development of Traditional Chinese medicine ("TCM") as its foundation, development of innovative drugs and medical technologies, as well as development of high-quality medical and healthcare services, striving to become a leading pharmaceutical enterprise that sets its footholds in China while seeking to expand its presence worldwide.


Copyright 2022 ACN Newswire. All rights reserved. http://www.acnnewswire.com

JBM Healthcare Announces FY2023 Interim Results

HONG KONG, Nov 25, 2022 – (ACN Newswire) – JBM (Healthcare) Limited ("JBM Healthcare" or the "Group"; Stock Code: 2161), a leading branded healthcare products marketer and distributor in Hong Kong, has announced today the interim results of the Group for the six months ended 30 September 2022 (the "Reporting Period").

KEY HIGHLIGHTS
— Period-on-period revenue up by 25%, totaled HK$236.8 million
— Profit attributable to equity shareholders increased by 116%, amounting to HK$21.6 million
— The Board declares an interim dividend of HK0.5 cent per share
— Proprietary Chinese medicines business witnessed robust growth of 53.1%
— Cross-border e-commerce business gained traction alongside expanded product offerings and growing customer traffic
— Foreseeable growth of traditional Chinese medicine (TCM) business bolstered by favourable policies for gaining access to Greater Bay Area markets.

Despite the lingering effects of the COVID-19 pandemic and the volatile economic sentiment in Hong Kong, the Group continued to perform in a resilient manner posting total revenue of HK$236.8 million in the Reporting Period, delivering a notable increase of 25% period-on-period. Profit attributable to equity shareholders also increased by 116% period-on-period to HK$21.6 million. Such growth was primarily due to the easing of local social distancing policies, which buttressed retail spending sentiment and led to a gradual recovery of the Group's overall sales, alongside a financial subsidy from the HKSAR Government through the Employment Support Scheme.

The Board declares the payment of an interim dividend for the six months ended 30 September 2022 of HK0.5 cent per share.

Resilient Performance Sustained by Robust Branded Portfolio
During the Reporting Period, the Group has made sound progress in developing its cross-border e-commerce platform, expanding the access of its products to a growing consumer base in Mainland China. Furthermore, the Group continued to implement its growth strategies to keep pace with consumer demand and market opportunities, further leveraging its unique strength to reinforce the Group's competitive position as a farsighted branded healthcare player in Asia. The promising performance was underpinned by the Group's brand management and strong commercial execution capabilities, as well as established sales network.

For the branded medicines business, sales revenue saw a decline of 10.3% period-on-period to HK$56.9 million, mainly due to the adverse impact of the pandemic on retail consumption in Hong Kong and Macau Nonetheless, the category-leading AIM Atropine Eye Drops brand continued to achieve promising growth realising 11.3% sales growth.

Regarding the proprietary Chinese medicines business, sales revenue delivered robust growth of 53.1%, amounting to HK$163 million, which was driven by strong momentum from its Concentrated Chinese Medicine Granules ("CCMG") business as a result of rising recognition and acceptance towards the adjunct therapeutic benefits of Chinese medicine amongst the general public. Our category leading brand, Po Chai Pills, also posted a remarkable growth of over 60% during the Reporting Period.

As for health and wellness products, sales revenue registered a decline of 13.3% to HK$16.9 million during the Reporting Period, which was mainly due to lower sales of certain products in the Hong Kong retail sector, though offset by growth from Oncotype DX and the Pantogar shampoo and tonic series. Oncotype DX posted a robust growth of 19.7% with a sustained momentum during the Reporting Period. With respect to Pantogar, an effective treatment for hair loss as substantiated by clinical studies, it also gained notable success via e-commerce platforms and professional hair salon channels. Pantogar sales was boosted by the launch of a new shampoo and tonic series that feature specialised formulations for women and men.

Accelerating E-commerce Development
The development of the Group's PRC cross-border e-commerce business continued to gather momentum as a result of its sustained efforts to drive expansion across product offerings, platform footholds, and customer traffic.

The two self-operated flagship stores on Tmall Global Marketplace and JD Worldwide achieved significant progress in expanding market share and customer base during the Reporting Period, bolstered by the effective operation and customer service support of its dedicated cross-border e-commerce team. The Group's flagship store has earned a top 8 ranking at Tmall, while Ho Chai Kung Tji Thung San has claimed a top 5 ranking in the pain-killer category of the platform during the Reporting Period.

The Group has continued to strengthen its partnership and operation with major PRC cross-border e-commerce platform customers, which witnessed a notable increase of pre-event purchase orders from B2B partners for the "6.18" and "Double 11" promotions during the Reporting Period. Apart from OTC products, the Group has been also actively enhancing its portfolio with products for tapping new potential categories to target a wider range of consumer groups. The Group's skincare and beauty products are currently sold through VIP Shop, a popular cross-border e-commerce platform for branded lifestyle products, and will be available via a growing array of cross-border e-commerce platforms.

Capturing Growth Potential of Chinese Medicines
The Group's proprietary Chinese medicine business also benefits from the government bureaus' collaborative support in facilitating the entry of Hong Kong's traditional proprietary Chinese medicines into the Greater Bay Area. Leveraging the streamlined measures for the Group's proprietary Chinese medicines portfolio to register with the Guangdong Provincial Medical Products Administration, it has successfully secured approval for registering its medicated oil brands Shiling Oil and Konsodona Medicated Oil in the Greater Bay Area.

Mr. Patrick Wong, Chief Executive Officer of JBM Healthcare, said, "In the wake of adverse market sentiments, pragmatism and persistence have never been more important as we navigate through the challenges that the pandemic has introduced to the business landscape. The pandemic has heightened health awareness and accelerated consumers' shift towards a more proactive approach in managing their health and wellness, which will further shore up self-care demand. The Group, as a key proprietary Chinese medicine and CCMG market player in Hong Kong, is also well poised to tap the burgeoning market in the Greater Bay Area, supported in part by favorable policies that encourage the development of TCM in the region and which will create more prospective business opportunities.

Looking ahead, we remain optimistic about the outlook for the healthcare industry. Adhering to our mission of enabling better health through self-care, we will continue to focus on developing our growth strategies based on the objectives of greater resilience and operational efficiency, and capitalise on market opportunities by helping consumers better manage their health through quality and well-trusted branded healthcare products."

About JBM (Healthcare) Limited (Stock Code: 2161)
JBM Healthcare is a Hong Kong-based company that markets and distributes branded healthcare products across Greater China, Southeast Asia and certain other countries. The Group is a unique field player with marketing expertise and a drug heritage that prioritises product efficacy and quality to meet consumers' healthcare needs. As a renowned healthcare brand operator in Hong Kong, the Group carries a wide-ranging portfolio of branded healthcare products comprising branded medicines, proprietary Chinese medicines and health and wellness products, which include well-recognised household brands such as Po Chai Pills, Ho Chai Kung Tji Thung San, Contractubex, BITE-X, Mederma Kids, Tong Tai Chung Woodlok Oil, Flying Eagle Woodlok Oil, Saplingtan, Shiling Oil and Konsodona Medicated Oil. JBM Healthcare has been a constituent stock of the MSCI Hong Kong Micro Cap Index since 27 May 2021. For more details about JBM Healthcare, please visit: www.jbmhealthcare.com.hk


Copyright 2022 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Tat Hong Equipment Service Co., Ltd. Announces 2022/23 Interim Results

HONG KONG, Nov 25, 2022 – (ACN Newswire) – Tat Hong Equipment Service Co., Ltd. ("Tat Hong" or the "Company", together with its subsidiaries, the "Group") (Stock Code: 2153), the first foreign-owned tower crane service provider established in the PRC, has announced its interim results for the six months ended 30 September 2022 (the "Period").

During the Period, the Group recorded revenue of approximately RMB 387.4 million, representing a decrease of approximately 6.8% as compared with that for the six months ended 30 September 2021. Loss attributable to equity shareholders of the Company for the period amounted to approximately RMB 41.9 million, mainly due to the one-off currency exchange loss on USD borrowings and the economic downturn caused by the COVID-19 pandemic (the "Pandemic"). The overall gross profit and gross profit margin decreased to RMB75.5 million and 19.5%, respectively.

The Group's total Tonne Metres (TM) in use increased from approximately 1,479,145 for the period ended 30 September 2021 to 1,577,983 for the period ended 30 September 2022. As at 30 September 2022, the Group had 292 projects in progress with a total outstanding contract value of approximately RMB 605 million and 37 projects on hand with a total expected contract value of approximately RMB 68 million. Of these projects, the Group expects to complete contract work of approximately RMB 348 million by the end of 30 September 2023, demonstrating solid earnings visibility.

Despite the gradual recovery in major economies and the surge in vaccination and immunity rates, the Pandemic has put pressure on every component of the Group's industry value chain. To contain the spread of the Pandemic throughout the country, numerous cities have adopted anti-pandemic measures, such as persistent or intermittent lockdowns, and certain projects were temporarily suspended on account of these measures. From April to June 2022, the Group's economic activities in eastern China were affected to a certain extent. In the meantime, against the backdrop of interest hikes by the US Fed and global inflation, economies around the world have encountered significant instability and pressure in the first half of the year. As the external environment remains volatile, the Group strives to adjust its operational strategy, optimise its management structure, and make timely and appropriate decisions in a bid to mitigate the risks brought by the Pandemic.

Mr. Sean Yau, CEO of Tat Hong Equipment Service Co., Ltd. said, "After years of the lingering Pandemic, the market remains sluggish and real estate has been severely impacted. Fortunately, the Group has optimised its business structure by placing a greater emphasis on the other business segments, reducing the real estate to approximately 30% of total revenue, which will mitigate the negative impact of the industry's downturn. In the meantime, we will shift our focus to the energy, infrastructure and public construction segments."

"With the continuous introduction of favourable policies and the development direction of the 14th Five Year Plan, which includes initiatives centred on 'new infrastructure, new urbanisation and major projects' and the aim of carbon neutrality, we believe that there are unexpected opportunities emerging in the (energy) infrastructure market. With our strong reputation and expertise, we are confident about the Group's prospects."

Mr. Roland Ng, Chairman of Tat Hong Equipment Service Co., Ltd. concluded, "Going forward, we will use the Pandemic as an opportunity to stimulate and accelerate transformation, to accelerate the adoption and improvement of the digital platform 'iSmartCon', so as to further optimise the management of various stages of the production process. Moreover, we will focus on analysing the impact of the Pandemic on each business sector and project, reviewing and modifying strategic plans, and communicating updates with all stakeholders including suppliers, clients and employees. The Group will continue its efforts in meeting the increasing customer demands for prefabricated construction using medium and large size tower cranes, and to establish a standardised post-market service eco-system for tower cranes, with the aim of providing a sustainable foundation for a green, safe and environmentally friendly tower crane service industry value chain, while adhering to the proper safety standards and PRC prevention and control policies."

About Tat Hong Equipment Service Co., Ltd. (Stock Code: 2153)
Tat Hong Equipment Service Co., Ltd. is the first foreign-owned tower crane service provider established in the PRC. Since 2007, the Group has established as a tower crane service provider for one-stop tower crane solution services from consultation, technical design, commissioning, construction to after-sales services primarily to Chinese Special-tier and Tier-1 EPC contractors. Guided by its core values, "Virtue, Safety and Excellence", the Group has successfully established its market position and maintained stable, reputable and loyal customer base in the construction industry in the PRC.


Copyright 2022 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Jacobson Pharma Announces FY2023 Interim Results

HONG KONG, Nov 25, 2022 – (ACN Newswire) – Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing and sale of essential medicines, specialty drugs and branded healthcare products, today announced the interim results of the Company and its subsidiaries (collectively the "Group") for the six months ended 30 September 2022 (the "Reporting Period").

KEY HIGHLIGHTS
— Revenue grew by 8.9% period-on-period, totaled HK$817.4 million
— Profit for the period up by 77.8%, amounted to HK$147.4 million
— Profit attributable to equity shareholders up by 70.2%, amounted to HK$136.2 million
— Sound financial position with net gearing ratio decreased from 29.2% to 20.8%
— The Board declares an interim dividend of HK2.8 cents per share
— Promising sales growth witnessed on certain key therapeutic lines including cardio-vascular, anti-diabetic as well as cold and flu products.
— Arsenic Trioxide Oral Solution, being the first specialty medicine made in the Group's PIC/S GMP plant alongside robust clinical substantiation, attained approval for use in designated hospitals in the Greater Bay Area

During the Reporting Period, the Group delivered total revenue of HK$817.4 million, which represented a period-on-period growth of 8.9%. Gross profit increased by 24.8% to HK$340.4 million, whilst profit attributable to equity shareholders amounted to HK$136.2 million, up by 70.2%, which was mainly attributed to the uplifted sales revenue, alongside the enhancement in product mix and operating leverage, coupled with the subsidies from the HKSAR Government pertinent to the Employment Support Scheme.

The Group maintains a healthy financial position as supported by its strong cash flows, with adjusted EBITDA of HK$290.5 million for the Reporting Period and the net gearing ratio decreased significantly from 29.2% as at 31 March 2022 to 20.8% as at the end of the Reporting Period. In addition, the Group has a sound cash position, with cash and cash equivalents of HK$860.4 million as at the end of the Reporting Period. The Board declares the payment of an interim dividend for the six months ended 30 September 2022 of HK2.8 cents per share, up by 133.3% as compared to HK1.2 cents of FY2022 Interim.

Robust Portfolio of Essential Medicines to Meet Healthcare Demand
During the reported period, the generic drugs business of the Group demonstrated resilient performance, driven by steady growth in both private and public sectors. Overall growth was benefitted from the easing of social distancing measures which facilitated the resumption of medical consultation visits in both public and private sectors in Hong Kong, thus boosting the demand for essential drugs as well as specialty medicines.

Amid the fifth wave of the epidemic outbreak, the Group geared up its production and supply of symptomatic relief medicines to cater for the increased public demand, which was reflected by the growth of 48.5% in the Group's range of cold and flu preparations in the public sector for the Reporting Period.

In addition, exhibiting a robust trend, medications for the aging population and chronic disease patients continued to present a strong demand. A case in point was that angiotensin II receptor antagonists and lipid-lowering products in the cardiovascular product class recorded a strong growth of 66.4% and 60.0% respectively in the private sector during the Reporting Period.

Steady Product Pipeline and Continuous Efforts in Portfolio Enhancement
As a continuous effort to meet the medical and patient needs with quality essential medicines, the Group launched a number of new products including Atorvastatin Tablet, Trimetazidine Modified Release Tablet, Olmesartan Tablets, Bicalutamide Tablet, Ofloxacin Ear Drop and Idarubicin Injection during the Reporting Period. Additionally, the Group has secured registration approval for 21 new products for upcoming market launches.

As of 30 September 2022, the Group has a total of 177 products in its research and development pipeline, among which 59 items have been approved for registration, 14 of them have been submitted for registration, 48 items have finished the development stage and are under stability preparation or stability study, and 27 items currently under formulation or pre-formulation research development stage.

Making In-roads into the Greater Bay Area
The Group's collaboration with the University of Hong Kong-Shenzhen Hospital in introducing its oral solution treatment for acute promyelocytic leukemia, Arsenic Trioxide Oral Solution, into designated hospitals in the Greater Bay Area has been given approval by Guangdong Province Medical Product Administration. This marked the first Hong Kong-made specialty medicine ever gained approval under the "Interim Regulations on the Administration for Importing Urgently Needed Clinical Drugs and Medical Devices from Hong Kong and Macao to the Guangdong-Hong Kong-Macao Greater Bay Area of Guangdong Province".

Formulation of ESG Strategy and Respective KPIs
As a corporate citizen that places long-term commitment to environmental, social and governance ("ESG") duties, Jacobson Pharma has formulated and progressed on its ESG strategy, "Jacobson 5 to Thrive", which underpins five priority areas, namely, product responsibility, commitment to employees, environmental stewardship, societal engagement and corporate governance duty. In response to such strategy, key performance indicators (KPIs) have been set and will continue to be evaluated from time to time in order to track respective progress on priority issues and programs, including greenhouse gas emissions, water and electricity usage, as well as utilisation of renewable energy.

Mr. Derek Sum, Chairman and Chief Executive Officer of Jacobson Pharma, noted, "Although COVID-19 has had an impact on the Group's business performance, we believe it will be transient. We are delighted that Jacobson Pharma achieved notable growth momentum in the first half of FY2023 amid the volatile economic sentiment. Thanks to the concerted effort of our teams, we delivered a resilient performance across both private and public sectors for our core business demonstrating an enhanced operational efficiency and a disciplined cost control.

"We remain positive about the future outlook of the healthcare industry and the growth prospect of the market for essential medicines. To capitalise on the emerging opportunities, we will continue to focus on advancing the Group's growth strategies and positioning it as an eminent provider of essential medicines and specialty drugs in Hong Kong and the Greater Bay Area."

About Jacobson Pharma Corporation Limited (Stock Code: 2633)
Jacobson Pharma is a leading pharmaceutical company in Hong Kong vertically integrated and engaged in the research, development, production, sale and distribution of essential medicines and specialty drugs. As a major provider of generic drugs in Hong Kong, the Group has one of the most extensive sales and distribution coverage for both the private and public sectors in Hong Kong, with an expanding reach into strategically selected Asian markets. Carrying a broad product portfolio and taking a pre-eminent market position in a number of therapeutic categories, the Group operates a host of 10 PIC/S GMP licensed production facilities for generic drugs in Hong Kong.

The Group aims at the continued strategic enrichment of its generic drug portfolios through the addition of high-value-added products. With its corporate headquarters based in Hong Kong, the Group has also established its operating subsidiaries in China, Macau, Taiwan and Cambodia, forming a regional commercial platform to tap the market potential in the Asia Pacific and Greater China region. Jacobson Pharma has been a constituent stock of MSCI Hong Kong Micro Cap Index since 1 June 2017. For more details about Jacobson Pharma, please visit the Group's website: http://www.jacobsonpharma.com


Copyright 2022 ACN Newswire. All rights reserved. http://www.acnnewswire.com